Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Week in Review: Taiwan Liposome Files for $50 Million IPO in the US
Taiwan Liposome (TW: 4152), a company developing extended-release delivery of known drugs, filed for a $50 million IPO on the NASDAQ exchange (see story). The company is already listed in
Everest Medicines, a US-China startup, in-licensed greater China rights to an antibiotic for serious multi-drug resistant infections from Boston's Tetraphase Pharma (NSDQ: TTPH) (see story). Everest made a $7 million upfront payment and will pay up to $16.5 million in regulatory milestones. It is also responsible for annual sales milestones of as much as $20 million. Formed last year, Everest is backed by a $50 million investment from C-Bridge Capital, a capital contribution that was described as the first tranche of a $130 million initial round.
Fosun International (HK: 0656), the parent of Shanghai Fosun Pharma (SHA: 600196; HK: 2196), formed a strategic life science collaboration with the
STA Pharma, the small-molecule drug manufacturing division of CRO WuXi AppTec, will collaborate with
Trials and Approvals
JHL Biotech, a Taiwan-China biosimilar company, received approval to begin a European (
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China